Hazards of dose escalation in prostate cancer radiotherapy

Deborah Kuban, Alan Pollack, Eugene Huang, Larry Levy, Lei Dong, George Starkschall, Isaac Rosen

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Purpose: To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications. Methods and Materials: Between 1987 and 1999, 1087 patients with clinical Stage T1b-T3 adenocarcinoma of the prostate were definitively irradiated without hormonal therapy and had a pretreatment serum prostate-specific antigen (PSA) and Gleason score recorded. The median follow-up was 65 months. Doses ranged from 64 to 78 Gy, with the treatment techniques corresponding to the year of therapy and the prescribed dose. A total of 301 patients were treated on a randomized protocol to either 70 or 78 Gy. Also, 163 patients were treated with three-dimensional conformal therapy and had dose-volume histograms available for review. Results: Tumor stage, grade, pretreatment PSA level, and radiation dose were all independent predictors of PSA disease-free survival (PSA-DFS) in multivariate analysis. The hazard rate for biochemical failure peaked at 1.5-3 years after radiotherapy. Although a statistically significant dose effect on PSA-DFS was found in the pretreatment PSA levels of those with both ≤10 ng/ mL and >10 ng/mL, in those with a pretreatment PSA ≤10 ng/mL, the improvement in outcome was only seen going from a dose level of 64-66 Gy to 68-70 Gy with a 5-year PSA-DFS rate of 66% vs. 81% (p <0.0001). This was also confirmed by the data from the randomized patients who showed no difference in outcome whether treated to 70 Gy or 78 Gy. In patients with a pretreatment PSA level >10 ng/mL, a statistically significant improvement was found in disease-free outcome among the 64-66-Gy, 68-70-Gy, and 78-Gy levels. PSA-DFS was approximately 50% better at each higher dose level at 5 and 8 years after treatment. The dose had a statistically significant impact in both intermediate- and high-risk groups. Rectal morbidity was both dose and volume related. Although at 5 years after therapy, the Grade 2-3 rectal complication rate was twice as high for patients treated to 78 Gy than to 70 Gy, 26% vs. 12%, this risk could be markedly diminished by adhering to dose-volume constraints. Conclusion: In intermediate- and high-risk prostate cancer patients, although it appears that radiation-dose escalation may improve PSA-DF outcome, the price paid in treatment morbidity can be high without adequate attention to dose-volume constraints of normal tissue. Care must be taken to consider not only the hazard of tumor recurrence but also that of complications.

Original languageEnglish
Pages (from-to)1260-1268
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume57
Issue number5
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
hazards
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
antigens
dosage
pretreatment
therapy
Therapeutics
Radiation
Morbidity
grade
Neoplasm Grading
tumors
Disease-Free Survival
Prostate
deuterium fluorides
Neoplasms

Keywords

  • Complications
  • Dose escalation
  • Prostate cancer
  • PSA-DFS

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Hazards of dose escalation in prostate cancer radiotherapy. / Kuban, Deborah; Pollack, Alan; Huang, Eugene; Levy, Larry; Dong, Lei; Starkschall, George; Rosen, Isaac.

In: International Journal of Radiation Oncology Biology Physics, Vol. 57, No. 5, 01.12.2003, p. 1260-1268.

Research output: Contribution to journalArticle

Kuban, Deborah ; Pollack, Alan ; Huang, Eugene ; Levy, Larry ; Dong, Lei ; Starkschall, George ; Rosen, Isaac. / Hazards of dose escalation in prostate cancer radiotherapy. In: International Journal of Radiation Oncology Biology Physics. 2003 ; Vol. 57, No. 5. pp. 1260-1268.
@article{b1f39f977f4842d9a26b11db9a51b5a9,
title = "Hazards of dose escalation in prostate cancer radiotherapy",
abstract = "Purpose: To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications. Methods and Materials: Between 1987 and 1999, 1087 patients with clinical Stage T1b-T3 adenocarcinoma of the prostate were definitively irradiated without hormonal therapy and had a pretreatment serum prostate-specific antigen (PSA) and Gleason score recorded. The median follow-up was 65 months. Doses ranged from 64 to 78 Gy, with the treatment techniques corresponding to the year of therapy and the prescribed dose. A total of 301 patients were treated on a randomized protocol to either 70 or 78 Gy. Also, 163 patients were treated with three-dimensional conformal therapy and had dose-volume histograms available for review. Results: Tumor stage, grade, pretreatment PSA level, and radiation dose were all independent predictors of PSA disease-free survival (PSA-DFS) in multivariate analysis. The hazard rate for biochemical failure peaked at 1.5-3 years after radiotherapy. Although a statistically significant dose effect on PSA-DFS was found in the pretreatment PSA levels of those with both ≤10 ng/ mL and >10 ng/mL, in those with a pretreatment PSA ≤10 ng/mL, the improvement in outcome was only seen going from a dose level of 64-66 Gy to 68-70 Gy with a 5-year PSA-DFS rate of 66{\%} vs. 81{\%} (p <0.0001). This was also confirmed by the data from the randomized patients who showed no difference in outcome whether treated to 70 Gy or 78 Gy. In patients with a pretreatment PSA level >10 ng/mL, a statistically significant improvement was found in disease-free outcome among the 64-66-Gy, 68-70-Gy, and 78-Gy levels. PSA-DFS was approximately 50{\%} better at each higher dose level at 5 and 8 years after treatment. The dose had a statistically significant impact in both intermediate- and high-risk groups. Rectal morbidity was both dose and volume related. Although at 5 years after therapy, the Grade 2-3 rectal complication rate was twice as high for patients treated to 78 Gy than to 70 Gy, 26{\%} vs. 12{\%}, this risk could be markedly diminished by adhering to dose-volume constraints. Conclusion: In intermediate- and high-risk prostate cancer patients, although it appears that radiation-dose escalation may improve PSA-DF outcome, the price paid in treatment morbidity can be high without adequate attention to dose-volume constraints of normal tissue. Care must be taken to consider not only the hazard of tumor recurrence but also that of complications.",
keywords = "Complications, Dose escalation, Prostate cancer, PSA-DFS",
author = "Deborah Kuban and Alan Pollack and Eugene Huang and Larry Levy and Lei Dong and George Starkschall and Isaac Rosen",
year = "2003",
month = "12",
day = "1",
doi = "10.1016/S0360-3016(03)00772-7",
language = "English",
volume = "57",
pages = "1260--1268",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Hazards of dose escalation in prostate cancer radiotherapy

AU - Kuban, Deborah

AU - Pollack, Alan

AU - Huang, Eugene

AU - Levy, Larry

AU - Dong, Lei

AU - Starkschall, George

AU - Rosen, Isaac

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Purpose: To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications. Methods and Materials: Between 1987 and 1999, 1087 patients with clinical Stage T1b-T3 adenocarcinoma of the prostate were definitively irradiated without hormonal therapy and had a pretreatment serum prostate-specific antigen (PSA) and Gleason score recorded. The median follow-up was 65 months. Doses ranged from 64 to 78 Gy, with the treatment techniques corresponding to the year of therapy and the prescribed dose. A total of 301 patients were treated on a randomized protocol to either 70 or 78 Gy. Also, 163 patients were treated with three-dimensional conformal therapy and had dose-volume histograms available for review. Results: Tumor stage, grade, pretreatment PSA level, and radiation dose were all independent predictors of PSA disease-free survival (PSA-DFS) in multivariate analysis. The hazard rate for biochemical failure peaked at 1.5-3 years after radiotherapy. Although a statistically significant dose effect on PSA-DFS was found in the pretreatment PSA levels of those with both ≤10 ng/ mL and >10 ng/mL, in those with a pretreatment PSA ≤10 ng/mL, the improvement in outcome was only seen going from a dose level of 64-66 Gy to 68-70 Gy with a 5-year PSA-DFS rate of 66% vs. 81% (p <0.0001). This was also confirmed by the data from the randomized patients who showed no difference in outcome whether treated to 70 Gy or 78 Gy. In patients with a pretreatment PSA level >10 ng/mL, a statistically significant improvement was found in disease-free outcome among the 64-66-Gy, 68-70-Gy, and 78-Gy levels. PSA-DFS was approximately 50% better at each higher dose level at 5 and 8 years after treatment. The dose had a statistically significant impact in both intermediate- and high-risk groups. Rectal morbidity was both dose and volume related. Although at 5 years after therapy, the Grade 2-3 rectal complication rate was twice as high for patients treated to 78 Gy than to 70 Gy, 26% vs. 12%, this risk could be markedly diminished by adhering to dose-volume constraints. Conclusion: In intermediate- and high-risk prostate cancer patients, although it appears that radiation-dose escalation may improve PSA-DF outcome, the price paid in treatment morbidity can be high without adequate attention to dose-volume constraints of normal tissue. Care must be taken to consider not only the hazard of tumor recurrence but also that of complications.

AB - Purpose: To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications. Methods and Materials: Between 1987 and 1999, 1087 patients with clinical Stage T1b-T3 adenocarcinoma of the prostate were definitively irradiated without hormonal therapy and had a pretreatment serum prostate-specific antigen (PSA) and Gleason score recorded. The median follow-up was 65 months. Doses ranged from 64 to 78 Gy, with the treatment techniques corresponding to the year of therapy and the prescribed dose. A total of 301 patients were treated on a randomized protocol to either 70 or 78 Gy. Also, 163 patients were treated with three-dimensional conformal therapy and had dose-volume histograms available for review. Results: Tumor stage, grade, pretreatment PSA level, and radiation dose were all independent predictors of PSA disease-free survival (PSA-DFS) in multivariate analysis. The hazard rate for biochemical failure peaked at 1.5-3 years after radiotherapy. Although a statistically significant dose effect on PSA-DFS was found in the pretreatment PSA levels of those with both ≤10 ng/ mL and >10 ng/mL, in those with a pretreatment PSA ≤10 ng/mL, the improvement in outcome was only seen going from a dose level of 64-66 Gy to 68-70 Gy with a 5-year PSA-DFS rate of 66% vs. 81% (p <0.0001). This was also confirmed by the data from the randomized patients who showed no difference in outcome whether treated to 70 Gy or 78 Gy. In patients with a pretreatment PSA level >10 ng/mL, a statistically significant improvement was found in disease-free outcome among the 64-66-Gy, 68-70-Gy, and 78-Gy levels. PSA-DFS was approximately 50% better at each higher dose level at 5 and 8 years after treatment. The dose had a statistically significant impact in both intermediate- and high-risk groups. Rectal morbidity was both dose and volume related. Although at 5 years after therapy, the Grade 2-3 rectal complication rate was twice as high for patients treated to 78 Gy than to 70 Gy, 26% vs. 12%, this risk could be markedly diminished by adhering to dose-volume constraints. Conclusion: In intermediate- and high-risk prostate cancer patients, although it appears that radiation-dose escalation may improve PSA-DF outcome, the price paid in treatment morbidity can be high without adequate attention to dose-volume constraints of normal tissue. Care must be taken to consider not only the hazard of tumor recurrence but also that of complications.

KW - Complications

KW - Dose escalation

KW - Prostate cancer

KW - PSA-DFS

UR - http://www.scopus.com/inward/record.url?scp=0344826614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344826614&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(03)00772-7

DO - 10.1016/S0360-3016(03)00772-7

M3 - Article

C2 - 14630260

AN - SCOPUS:0344826614

VL - 57

SP - 1260

EP - 1268

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -